Over 400 CML patients (at diagnosis and during/after therapy) entered this cross-sectional study in which CD26 expression was evaluated by a standardized multiparametric flow cytometry analysis on PB CD45+/CD34+/CD38− stem cell population. The gene discussed is PTPRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.